Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 2/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | NQO1 | P15559 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17400969 | 0.86 | NQO1 (0.61) | NQO1ALDH1A1MAPT | |
| SCHEMBL16519363 | 0.84 | NQO1 (0.46) | NQO1CYP1A2ALDH1A1MAOBMAPT | |
| SCHEMBL14952746 | 0.83 | KMT2A (0.44) | FFAR1NQO1ALDH1A1MAPK1MAPT | |
| SCHEMBL8344905 | 0.83 | DRD4 (0.37) | SCN4AFFAR1SIGMAR1MAPK1KCNH2 | |
| SCHEMBL5779539 | 0.82 | USP2 (0.45) | FFAR1NQO1CYP1A2PPARGPPARA | |
| SCHEMBL1951190 | 0.82 | CYP2C9 (0.50) | NQO1ALDH1A1MAPK1MAPT | |
| SCHEMBL3776385 | 0.81 | LTA4H (0.48) | NQO1CYP1A2ALDH1A1MAPK1 | |
| SCHEMBL20539545 | 0.81 | APP (0.44) | NQO1PPARA | |
| SCHEMBL2329756 | 0.81 | CYP1A2 (0.47) | NQO1CYP1A2MAOB | |
| SCHEMBL17400983 | 0.81 | NQO1 (0.43) | NQO1PPARAALDH1A1MAOBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2681207-B1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2016-12-28 | — | — | EP | disclosed |
| US-8912188-B2 | Substituted quinoxaline carboxylic acids for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912188-B2 | Substituted quinoxaline carboxylic acids for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912188-B2 | Substituted quinoxaline carboxylic acids for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| EP-2681207-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | Bioenergenix (US) | 2014-01-08 | — | — | EP | disclosed |
| US-20130046103-A1 | PREPARATION OF BENZOFURANS AND USE THEREOF AS SYNTHETIC INTERMEDIATES | MAPI PHARMA LIMITED (IL) | 2013-02-21 | — | — | US | disclosed |
| EP-2533636-A1 | PREPARATION OF BENZOFURANS AND USE THEREOF AS SYNTHETIC INTERMEDIATES | Mapi Pharma Limited (IL) | 2012-12-19 | — | — | EP | disclosed |
| US-20120232056-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232056-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232056-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-09-13 | — | — | US | disclosed |
| WO-2012119046-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-09-07 | — | — | WO | disclosed |
| WO-2012119046-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-09-07 | — | — | WO | disclosed |
| WO-2011099010-A1 | PREPARATION OF BENZOFURANS AND USE THEREOF AS SYNTHETIC INTERMEDIATES | MAPI PHARMA HOLDINGS (CYPRUS) LIMITED (CY) | 2011-08-18 | — | — | WO | disclosed |
| WO-2004069829-A1 | (2S)-2-((PYRIMIDIN-4-YL)AMINO)-4-METHYLPENTANOIC ACID AMINOETHYLAMID DERIVATIVES AS IL-8 RECEPTOR MODULATORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND RHEUMATOID ARTHRITIS | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1302462-A1 | SULFONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-4511575-A | Antidiabetic pyrrolecarboxylic acids | PFIZER INC. (US) | 1985-04-16 | — | — | US | disclosed |
| US-4511576-A | Antidiabetic pyrrolecarboxylic acids | PFIZER INC. (US) | 1985-04-16 | — | — | US | disclosed |
| US-4351843-A | LOWERING BLOOD GLUCOSE | PFIZER INC. (US) | 1982-09-28 | — | — | US | disclosed |
| US-4282242-A | HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1981-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130046103-A1 | PREPARATION OF BENZOFURANS AND USE THEREOF AS SYNTHETIC INTERMEDIATES | CYP2F1, CYP4F3, CYP2D6 | SCN4A 764/4885FFAR1 3093/4885NQO1 242/4885 |
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | SULT1E1, RRS1, SHH | SCN4A 664/4885FFAR1 1851/4885NQO1 910/4885 |
| US-20120232056-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | SCN4A 3748/4885FFAR1 3260/4885NQO1 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.